BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11131151)

  • 1. Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells.
    Kaufmann AM; Gissmann L; Simms P; Schreckenberger C; Qiao L
    Immunobiology; 2000 Nov; 202(4):339-52. PubMed ID: 11131151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro.
    Kaufmann AM; Gissmann L; Street D; Schreckenberger C; Hunter M; Qiao L
    Cell Immunol; 1996 May; 169(2):246-51. PubMed ID: 8620552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of IL-7 and IL-12 on human T cell activation.
    Mehrotra PT; Grant AJ; Siegel JP
    J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
    Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity.
    Lindauer M; Rudy W; Gückel B; Doeberitz MV; Meuer SC; Moebius U
    Immunology; 1998 Mar; 93(3):390-7. PubMed ID: 9640250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
    Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
    Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells.
    Miyazono Y; Kamogawa Y; Ryo K; Furukawa T; Mitsuhashi M; Yamauchi K; Kameoka T; Hayashi N
    J Gastroenterol Hepatol; 1999 Oct; 14(10):997-1003. PubMed ID: 10530496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma.
    Rudy W; Gückel B; Siebels M; Lindauer M; Meuer SC; Moebius U
    Int Immunol; 1997 Jun; 9(6):853-60. PubMed ID: 9199968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD8+ T cells.
    Komata T; Tanaka R; Yamamoto K; Oda T; Ono K; Yoshida S; Takahashi M
    J Immunother; 1997 Jul; 20(4):256-64. PubMed ID: 9220315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of immunogenicity of Jeg3 cells by ectopic expression of HLA-A*0201 and CD80.
    Koc S; Kather A; Markert UR; Dürst M; Schneider A; Kaufmann AM
    Am J Reprod Immunol; 2003 Sep; 50(3):243-53. PubMed ID: 14629030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells.
    Takenoyama M; Yoshino I; Eifuku R; So T; Imahayashi S; Sugaya M; Yasuda M; Inoue M; Ichiyoshi Y; Osaki T; Nagashima A; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 2001 Mar; 92(3):309-15. PubMed ID: 11267941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD80-mediated induction of immunostimulation in two ocular melanoma cell lines is augmented by interferon-gamma.
    Mulcahy KA; Alexander S; Platts KE; Wardle C; Sisley K; Rennie IG; Murray AK
    Melanoma Res; 2002 Apr; 12(2):129-38. PubMed ID: 11930109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function.
    Lang TJ; Nguyen P; Peach R; Gause WC; Via CS
    J Immunol; 2002 Apr; 168(8):3786-92. PubMed ID: 11937530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
    Pettit SJ; Ali S; O'Flaherty E; Griffiths TR; Neal DE; Kirby JA
    Clin Exp Immunol; 1999 Apr; 116(1):48-56. PubMed ID: 10209504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
    Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
    J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
    Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
    Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12.
    Joki T; Kikuchi T; Akasaki Y; Saitoh S; Abe T; Ohno T
    Int J Cancer; 1999 Aug; 82(5):714-20. PubMed ID: 10417770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
    J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.